Advertisement
HCM vs SFOSF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a Buy and SFOSF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HCM’s FA Score shows that 1 FA rating(s) are green whileSFOSF’s FA Score has 1 green FA rating(s).
- HCM’s FA Score: 1 green, 4 red.
- SFOSF’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HCM’s TA Score shows that 4 TA indicator(s) are bullish while SFOSF’s TA Score has 0 bullish TA indicator(s).
- HCM’s TA Score: 4 bullish, 4 bearish.
- SFOSF’s TA Score: 0 bullish, 2 bearish.
Price Growth
HCM (@Pharmaceuticals: Other) experienced а +0.11% price change this week, while SFOSF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.53%. For the same industry, the average monthly price growth was +11.98%, and the average quarterly price growth was +75.52%.
Reported Earning Dates
HCM is expected to report earnings on Aug 07, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+3.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| HCM | SFOSF | HCM / SFOSF | |
| Capitalization | 2.88B | 10.9B | 26% |
| EBITDA | 67.3M | 6.12B | 1% |
| Gain YTD | 22.207 | 8.593 | 258% |
| P/E Ratio | 27.95 | 11.75 | 238% |
| Revenue | 838M | 44.4B | 2% |
| Total Cash | 886M | 16.1B | 6% |
| Total Debt | 86.1M | 30.8B | 0% |
HCM | SFOSF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 88 | 80 | |
PRICE GROWTH RATING 1..100 | 44 | 52 | |
P/E GROWTH RATING 1..100 | 5 | 78 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SFOSF's Valuation (23) in the null industry is significantly better than the same rating for HCM (90) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew significantly faster than HCM’s over the last 12 months.
SFOSF's Profit vs Risk Rating (100) in the null industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.
SFOSF's SMR Rating (80) in the null industry is in the same range as HCM (88) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.
HCM's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as SFOSF (52) in the null industry. This means that HCM’s stock grew similarly to SFOSF’s over the last 12 months.
HCM's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for SFOSF (78) in the null industry. This means that HCM’s stock grew significantly faster than SFOSF’s over the last 12 months.
| HCM | SFOSF | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | N/A |
| Momentum ODDS (%) | 2 days ago 75% | N/A |
| MACD ODDS (%) | 2 days ago 67% | N/A |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 44% |
| Advances ODDS (%) | 9 days ago 73% | N/A |
| Declines ODDS (%) | 4 days ago 81% | N/A |
| BollingerBands ODDS (%) | 2 days ago 75% | N/A |
| Aroon ODDS (%) | 2 days ago 72% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EDV | 64.67 | 0.53 | +0.83% |
| Vanguard Extended Duration Trs ETF | |||
| HDUS | 61.35 | 0.21 | +0.34% |
| Hartford Disciplined US Equity ETF | |||
| LRGC | 74.29 | 0.24 | +0.33% |
| AB US Large Cap Strategic Equities ETF | |||
| RSJN | 33.42 | 0.09 | +0.27% |
| FT Vest U.S. Eq Eq Wght Buffr ETF - Jun | |||
| BCIL | 30.15 | -0.19 | -0.63% |
| Bancreek International Large Cap ETF | |||
HCM and
Correlation & Price change
A.I.dvisor tells us that HCM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and ACET's prices will move in lockstep.
| Ticker / NAME | Correlation To HCM | 1D Price Change % | ||
|---|---|---|---|---|
| HCM | 100% | -0.96% | ||
| ACET - HCM | 29% Poorly correlated | -1.90% | ||
| TLRY - HCM | 27% Poorly correlated | -2.03% | ||
| CGC - HCM | 26% Poorly correlated | +2.70% | ||
| OGI - HCM | 25% Poorly correlated | +1.32% | ||
| ACB - HCM | 25% Poorly correlated | +0.62% | ||
More | ||||